JP5671487B2 - 放射線治療の有効性を増強するためのｍｅｔ阻害剤 - Google Patents

放射線治療の有効性を増強するためのｍｅｔ阻害剤 Download PDF

Info

Publication number
JP5671487B2
JP5671487B2 JP2012039193A JP2012039193A JP5671487B2 JP 5671487 B2 JP5671487 B2 JP 5671487B2 JP 2012039193 A JP2012039193 A JP 2012039193A JP 2012039193 A JP2012039193 A JP 2012039193A JP 5671487 B2 JP5671487 B2 JP 5671487B2
Authority
JP
Japan
Prior art keywords
met
met inhibitor
nucleic acid
nucleotide sequence
sequence encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012039193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012196206A (ja
JP2012196206A5 (enExample
Inventor
カルラ・ボッカッチョ
パオロ・マリア・コモリオ
フィオレッラ・ペトロンツェッリ
リータ・デ・サンティス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metheresis Translational Research SA
Original Assignee
Metheresis Translational Research SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metheresis Translational Research SA filed Critical Metheresis Translational Research SA
Publication of JP2012196206A publication Critical patent/JP2012196206A/ja
Publication of JP2012196206A5 publication Critical patent/JP2012196206A5/ja
Application granted granted Critical
Publication of JP5671487B2 publication Critical patent/JP5671487B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2012039193A 2011-03-18 2012-02-24 放射線治療の有効性を増強するためのｍｅｔ阻害剤 Active JP5671487B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11158861.2 2011-03-18
EP11158861.2A EP2500036B1 (en) 2011-03-18 2011-03-18 MET inhibitors for enhancing radiotherapy efficacy

Publications (3)

Publication Number Publication Date
JP2012196206A JP2012196206A (ja) 2012-10-18
JP2012196206A5 JP2012196206A5 (enExample) 2013-02-14
JP5671487B2 true JP5671487B2 (ja) 2015-02-18

Family

ID=44260211

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012039193A Active JP5671487B2 (ja) 2011-03-18 2012-02-24 放射線治療の有効性を増強するためのｍｅｔ阻害剤

Country Status (22)

Country Link
US (1) US20120237524A1 (enExample)
EP (1) EP2500036B1 (enExample)
JP (1) JP5671487B2 (enExample)
KR (1) KR101540838B1 (enExample)
CN (1) CN102688491A (enExample)
AU (1) AU2012201303B2 (enExample)
BR (1) BR102012006063B1 (enExample)
CA (1) CA2769991C (enExample)
CY (1) CY1115374T1 (enExample)
DK (1) DK2500036T3 (enExample)
EA (1) EA028590B1 (enExample)
ES (1) ES2489475T3 (enExample)
HR (1) HRP20140729T1 (enExample)
IL (1) IL218293A (enExample)
MX (1) MX2012003084A (enExample)
PL (1) PL2500036T3 (enExample)
PT (1) PT2500036E (enExample)
RS (1) RS53468B (enExample)
SG (1) SG184637A1 (enExample)
SI (1) SI2500036T1 (enExample)
SM (1) SMT201400106B (enExample)
ZA (1) ZA201201992B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN110320365B (zh) * 2019-07-06 2022-07-22 湖南莱拓福生物科技有限公司 NF-κB RelA/p65蛋白位点特异性磷酸化诊断试剂盒
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
MXPA05008521A (es) * 2003-02-13 2005-10-20 Pharmacia Corp Anticuerpos a c-met para el tratamiento de canceres.
EA015363B1 (ru) * 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
ES2368864T3 (es) * 2006-02-06 2011-11-23 Metheresis Translational Research Sa Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.
EP2019116A1 (en) * 2007-07-26 2009-01-28 Helmholtz-Zentrum für Infektionsforschung GmbH Inhibitor of the met-receptor and its use

Also Published As

Publication number Publication date
ZA201201992B (en) 2015-05-27
SMT201400106B (it) 2014-11-10
SG184637A1 (en) 2012-10-30
BR102012006063A8 (pt) 2022-11-08
KR20120106582A (ko) 2012-09-26
HRP20140729T1 (hr) 2014-08-29
IL218293A (en) 2016-06-30
JP2012196206A (ja) 2012-10-18
DK2500036T3 (da) 2014-08-04
ES2489475T3 (es) 2014-09-02
EA201200329A2 (ru) 2012-09-28
CY1115374T1 (el) 2017-01-04
PL2500036T3 (pl) 2014-10-31
EA028590B1 (ru) 2017-12-29
HK1174539A1 (en) 2013-06-14
SI2500036T1 (sl) 2014-09-30
BR102012006063B1 (pt) 2023-03-07
KR101540838B1 (ko) 2015-08-06
PT2500036E (pt) 2014-08-25
RS53468B (sr) 2014-12-31
BR102012006063A2 (pt) 2021-11-16
US20120237524A1 (en) 2012-09-20
AU2012201303A1 (en) 2012-10-04
CA2769991A1 (en) 2012-09-18
EA201200329A3 (ru) 2013-01-30
EP2500036B1 (en) 2014-05-07
IL218293A0 (en) 2012-07-31
EP2500036A1 (en) 2012-09-19
MX2012003084A (es) 2012-09-17
AU2012201303B2 (en) 2013-11-07
CN102688491A (zh) 2012-09-26
CA2769991C (en) 2018-05-15

Similar Documents

Publication Publication Date Title
JP2012196206A (ja) 放射線治療の有効性を増強するためのｍｅｔ阻害剤
Pei et al. Angiotensin-(1-7) decreases cell growth and angiogenesis of human nasopharyngeal carcinoma xenografts
US11185585B2 (en) Methods and compositions for improving antiangiogenic therapy with anti-integrins
AU2009299744B2 (en) Inhibition of PLGF to treat Philadelphia chromosome positive leukemia
JP2024133495A (ja) 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール
CN112543809A (zh) 包含C/EBPα saRNA的组合疗法
Sangaletti et al. Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis
US20210212997A1 (en) Methods of enhancing immunity
CN113717252B (zh) 一种cd44拮抗多肽及其衍生物与应用
JP5579699B2 (ja) 分子標的薬に対する感受性が低下している癌の治療薬および分子標的薬に対する感受性を増強する医薬組成物
Stockwell et al. Therapeutic approaches for targeting the pediatric brain tumor microenvironment
Choi et al. Context-dependent roles for autophagy in myeloid cells in tumor progression
CN110522750B (zh) TNFα小分子抑制剂C87在制备治疗脑胶质瘤药物方面的应用
HK1174539B (en) Met inhibitors for enhancing radiotherapy efficacy
Mongiardi et al. Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing. Cancers 2021, 13, 484
US20110044991A1 (en) Methods and compositions for treating lymphoma and myeloma
CN106138045A (zh) 通过靶向mTOR操纵肿瘤微环境以消除肿瘤耐药性的方法及制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140909

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141219

R150 Certificate of patent or registration of utility model

Ref document number: 5671487

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250